AstraZeneca Annual Report and Operational Review Form 20-F Information 2003 09 Operational Review The growing demand for new medicines AstraZeneca focuses its skills, experience This Operational Review pages 9 to 30 is driven by increasing populations and and resources on six therapy areas: provides detailed information about our improved life expectancy as modern Cardiovascular, Gastrointestinal, research, development, manufacturing and medicine supports an ageing population.
Neuroscience, Oncology, Respiratory and marketing activities worldwide and our According to the latest information Inflammation, and Infection which represent performance in 2003. available from the World Health the majority of the worldwide burden of Organisation www.
We have a powerful range of Contents Page greatest burden of disease is in the products that meet patient needs in our Therapy areas: non-communicable disease sector chosen areas of activity including some Cardiovascular 10 where diseases such as unipolar significant areas of hitherto unmet medical Gastrointestinal 12 depression, schizophrenia, diabetes, need.
We are committed to delivering Neuroscience 14 ischaemic heart disease, cerebrovascular new, medically important and commercially Oncology 16 disease and asthma have all increased successful products to the market Respiratory and Inflammation 18 over the last five years.
Infection 20 diseases are also increasing due primarily Geographic Review 21 to HIV AIDS and tuberculosis.
Research and Development 23 Commercialisation and Portfolio Management 26 Supply and Manufacturing 27 Other Businesses, Main Facilities and Intellectual Property 28 Industry Regulation 29 Corporate Responsibility 30 AstraZeneca in brief We spend around Collaborations with leading We have over 60,000 $14 million each working academic centres and employees worldwide: day on research and biotechnology companies development total R&D and the in-licensing of 35,000 in Europe spend in 2003: $3.5 billion innovative products and technologies complement 18,000 in the Americas We employ 11,600 our in-house capabilities and people in research and play a key role in 8,000 in Asia, Africa development at 11 R&D strengthening our portfolio and Australasia centres in seven countries: Sweden, the UK, the US, We have 31 manufacturing We sell in over 100 countries Canada, France, India sites in 20 countries and Japan Along with our commitment Around 16,000 people to competitiveness and Our strong R&D pipeline worldwide work in supply high performance, we will includes a number of and manufacturing, including continue to be led by our significant innovations some 13,000 people in core values to achieve formulation and packaging, sustainable success We have 12 projects in and 1,750 in active phase 2 and 28 projects pharmaceutical ingredient in phase 3 development, supply as shown on page 24
